Werewolf Therapeutics is a technology company.
Werewolf Therapeutics has raised $128.0M across 2 funding rounds.
Werewolf Therapeutics has raised $128.0M in total across 2 funding rounds.
Werewolf Therapeutics has raised $128.0M in total across 2 funding rounds.
Werewolf Therapeutics's investors include RA Capital, Deerfield Management, Hercules Capital, MPM Capital.
Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated biologic therapies to stimulate the immune system against cancer and immune-mediated conditions.[1][2][3] It engineers INDUKINE™ and INDUCER™ molecules using its proprietary PREDATOR® platform, which remain inactive systemically but activate selectively in the tumor microenvironment to enhance efficacy and minimize toxicities of cytokines like IL-2, IL-12, and IFNα.[2][3][7] The company serves cancer patients with solid tumors, addressing unmet needs in immunotherapy by targeting limitations of conventional proinflammatory therapies.[1][2] Its lead candidates, WTX-124 (IL-2 INDUKINE™) and WTX-330 (IL-12 INDUKINE™), are in Phase 1/2 trials showing early promise, including a confirmed partial response in metastatic gall bladder cancer, with a cash runway into Q4 2026 supporting pipeline advancement.[3][4][7]
Werewolf Therapeutics emerged from innovative science analogized to a werewolf: molecules that lie dormant systemically but transform into potent predators in tumors.[2] Founded as an oncology biotherapeutics company, it leverages the PREDATOR® protein engineering platform invented by its experienced scientists to create next-generation cancer treatments.[2][3][6] Key leadership includes Dan Hicklin, PhD, President and CEO, who has guided the company through clinical development, emphasizing tumor-activated immunotherapies.[3] Early traction stems from advancing WTX-124 into trials, demonstrating tolerability and responses in refractory cancers, with pivotal updates as of December 2025.[3]
Werewolf rides the immuno-oncology wave, where immunotherapy advances like checkpoint inhibitors face challenges from off-target toxicities and limited responses in "cold" tumors.[2][3] Its conditional activation addresses historical cytokine failures (e.g., severe toxicity of recombinant IL-2/IL-12), aligning with market forces favoring targeted, systemically delivered therapies amid growing demand for safer options in refractory cancers.[1][2][4] Timing benefits from maturing T-cell engager tech and FDA pathways for accelerated approval, positioning Werewolf to influence the ecosystem by pioneering "precision immuno-oncology" for immunologically unresponsive indications.[1][3][4]
Werewolf's 2026 priorities center on WTX-124 data from over 100 patients (Q4 2025 updates), WTX-330 Phase 1b/2 enrollment (NCT06939283), and expanding INDUCER™/INDUKINE™ pipelines into new antigens like CDH6 and IFNα.[3][4][7] Trends like AI-driven protein engineering and combo regimens with checkpoints will shape progress, potentially evolving its influence toward leadership in tumor-selective immunomodulators if clinical momentum sustains.[3][4] This targeted immune "transformation" could redefine cancer care, fulfilling its mission to pioneer safer, potent therapies.[1][2]
Werewolf Therapeutics has raised $128.0M across 2 funding rounds. Most recently, it raised $72.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $72.0M Series B | RA Capital | |
| Nov 1, 2019 | $56.0M Series A | Deerfield Management, Hercules Capital, MPM Capital |